CORAL GABLES, Fla., Oct. 28, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has agreed to sell: (i) 3,046,740 shares of its common stock, and (ii) common stock purchase warrants to purchase an aggregate of 1,523,370 shares of the Company’s common stock, in a firm commitment underwritten public offering. The offering price for each share and corresponding warrant was $1.15, and the gross proceeds raised in the offering was $3,503,751. After underwriting discounts and commissions and expenses of the offering payable by the Company, Catalyst expects to receive net proceeds of approximately $3,150,000. Catalyst expects to use the net proceeds from this offering to fund costs associated with the Company’s currently ongoing clinical trials and studies and for general corporate purposes.
